Napon Hiranburana

Napon Hiranburana

Auto-generated profile, based on publicly available information

Napon Hiranburana

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research and Infectious Diseases Centre, Bangkok 10330, Thailand

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
NHNapon Hiranburana
Napon Hiranburana
JSJiratchaya Sophonphan
Jiratchaya Sophonphan
SKStephen Kerr
Stephen Kerr
SUSasiwimol Ubolyam
Sasiwimol Ubolyam
WUWarat Usawakidwiree
Warat Usawakidwiree
AAAnchalee Avihingsanon
Anchalee Avihingsanon
Background: The N-Acetyltransferase (NAT2) slow acetylator phenotype has been associated with a higher risk of isoniazid (INH)-induced hepatotoxicity. We investigated the association between NAT2 genotypes with inferred acetylator status, hepatotoxicity, and INH pharmacokinetics in Thai people living with HIV (PLWH) receiving INH-based Tuberculosis (TB) preventive or treatment regimens. Methods: In this prospective cohort study of Thai PLWH initiating INH-based regimens; NAT2 genotyping classified participants as slow (SA), intermediate (IA), or rapid acetylators (RA). Hepatotoxicity was defined as transaminase elevations more than 2.5 times the upper limit of normal (ULN). Multivariable logistic regression identified genotypes and factors associated with hepatotoxicity. A pharmacokinetic (PK) substudy assessed INH exposure across phenotypes. Results: Of 894 participants, 32.4% were SA, 41.2% IA, and 26.4% RA. Hepatotoxicity occurred in 10.9% overall and was highest in SA (15.2%). SA had increased hepatotoxicity risk versus RA (adjusted odds ratio [aOR] 2.43; 95% CI: 1.32–4.48). Genotypes NAT2*6A/*6A (aOR 1.84) and NAT2*7B/*7B (aOR 4.46) were associated with increased risk; NAT2*4/*4 was protective (aOR 0.33). Other independent risk factors included high baseline alanine aminotransferase (ALT), HCV co-infection, 2HRZE/4HR regimen (vs 1HP), and efavirenz-based antiviral therapy (vs dolutegravir). In the PK substudy (n = 93), INH exposure assessed by the area under the concentration time curve from 0 to 24 h, was significantly increased by approximately 2-fold in SA, regardless of anti-TB regimen. Conclusions: NAT2 SA phenotype, particularly *6A/*6A and *7B/*7B genotypes, is associated with an increased risk of anti-tuberculosis-induced hepatotoxicity and higher INH exposure in Thai PLWH. Incorporating NAT2-guided dosing may enhance safety of INH-containing regimens in PLWH.

18 March 2026 in Journal of Infection and Public Health
Verified
Journal Article
Open access
NRNitis Rattanagitpaisan
Nitis Rattanagitpaisan
NSNopporn Songumpai
Nopporn Songumpai
KPKobpat Phadungsaksawasdi
Kobpat Phadungsaksawasdi
KMKornvalee Meesilpavikkai
Kornvalee Meesilpavikkai
NHNapon Hiranburana
Napon Hiranburana
Kanok PreativatanyouKanok Preativatanyou
Kanok Preativatanyou
Differentiation between leishmaniasis and histoplasmosis remains a significant diagnostic conundrum, especially in immunosuppressed patients, due to overlapping clinical presentations and histopathological features. We report a case of a 53-year-old Thai man with advanced HIV disease from Southern Thailand who presented in 2020 with a chronic palate ulcer and hard palate perforation, initially diagnosed as histoplasmosis and treated with itraconazole for a year. Three years later (2023), the patient developed systemic symptoms, and biopsies confirmed visceral leishmaniasis. Given the increasing number of autochthonous leishmaniasis cases, the patient's original diagnosis from 2020 was reexamined. Retrospective analysis of the original palate biopsy revealed amastigotes with kinetoplasts, whereas PAS and GMS staining were negative for fungi, excluding histoplasmosis. Molecular diagnostics, which combined PCR for Leishmania spp. and Histoplasma capsulatum with Sanger sequencing, confirmed Leishmania martiniquensis and ruled out Histoplasma capsulatum, leading to a corrected diagnosis of mucocutaneous leishmaniasis. This report documents the second case of mucocutaneous leishmaniasis caused by L. martiniquensis in Thailand, with primary mucocutaneous presentation that progressed to visceral involvement. This highlights diagnostic challenges due to morphological similarities between Leishmania amastigotes and Histoplasma capsulatum yeasts, emphasizing the need for integrative histopathological (including specific staining techniques) and molecular diagnostics for accurate diagnosis and effective treatment.

20 November 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ACAnan Chanruang
Anan Chanruang
ABAngela Birnbaum
Angela Birnbaum
SSSasithorn Sirilun
Sasithorn Sirilun
Suthunya ChupraditSuthunya Chupradit
Suthunya Chupradit
SUSasiwimol Ubolyam
Sasiwimol Ubolyam
BPBaralee Punyawudho
Baralee Punyawudho
Background/Objectives: Dolutegravir (DTG) is recommended as first-line treatment for Thai people living with HIV (PLWH). Real-world studies show high plasma concentration variability, which may increase neuropsychiatric adverse effects. This variability can be influenced by both genetic and nongenetic factors, but data for the Thai population are insufficient. We investigated factors associated with DTG pharmacokinetics in Thai PLWH. Methods: A cross-sectional analysis was conducted in Thai PLWH receiving a 50 mg DTG-based regimen. Intensive blood sampling was performed to determine DTG pharmacokinetic parameters using a non-compartmental analysis. Genotyping for UGT1A1, ABCG2, and NR1I2 was performed. Univariable and multivariable linear regression analyses were used to identify factors associated with DTG pharmacokinetics. Results: A total of 104 Thai PLWH were included. Multivariable analysis demonstrated that both the UGT1A1 poor metabolizer phenotype and body weight were independently associated with DTG exposure. After adjusting for body weight, the UGT1A1 poor metabolizer phenotype was associated with increases of 5.18% in AUC0–24 and 20.59% in Ctrough. No significant association was found between the ABCG2 421 C>A polymorphism and DTG pharmacokinetic parameters. Conclusions: Body weight and the UGT1A1 poor metabolizer phenotype significantly impacted DTG exposure in Thai PLWH. Those with the UGT1A1 poor metabolizer, particularly with lower body weight, had significantly increased DTG exposures. These findings highlight that dose optimization may be worth exploring in selected individuals in this population.

1 April 2026 in Journal of the International AIDS Society
Verified
Journal Article
Open access
TATanakorn Apornpong
Tanakorn Apornpong
WHWin Min Han
Win Min Han
AHAkarin Hiransuthikul
Akarin Hiransuthikul
HLHay Mar Su Lwin
Hay Mar Su Lwin
NHNapon Hiranburana
Napon Hiranburana
AAAnchalee Avihingsanon
Anchalee Avihingsanon
Introduction: Frailty is highly prevalent among older people with HIV (PWH), driven by multimorbidity and HIV‐associated accelerated ageing. We investigated frailty transitions and associated factors over a 5‐year follow‐up period in an ageing cohort of PWH in Thailand. Methods: We conducted a prospective cohort study among PWH aged ≥50 years in Bangkok, Thailand, between May 2015 and June 2024. Frailty phenotypes were assessed at baseline and at 5 years of follow‐up using the Fried frailty phenotype, including unintentional weight loss, low physical activity, exhaustion, weak grip strength and slow walking speed. Multinomial logistic regression was performed to identify factors associated with frailty progression and reversibility over follow‐up. Results: Among 324 participants enrolled (63% male; median age of 54 [IQR, 52−59] years), 158 (49%) were robust, 153 (47%) were pre‐frailty and 13 (4%) were frailty at baseline. Over 5 years, 111 participants (34%) experienced frailty worsening, 158 (49%) remained stable and 55 (17%) demonstrated frailty reversal. Among 158 PWH who were robust at baseline, 75 (47%) remained robust, 57 (36%) transitioned to pre‐frailty and 26 (16%) progressed to frailty. Notably, among those frail at baseline ( N = 13), 65% improved to pre‐frailty or robustness. Low physical activity was the most common frailty component at baseline, while weak grip strength was the most predominant frailty phenotype at year 5. In multivariable analysis, multimorbidity (adjusted odds ratio [aOR] 3.09, 95% confidence interval [CI]: 1.42−6.72, p = 0.004), antiretroviral therapy (ART) duration>20 years (aOR 1.82, 95% CI: 1.08−3.06, p = 0.025) and baseline vitamin D deficiency (aOR 1.85, 95% CI: 1.10−3.10, p = 0.019) were independently associated with increased frailty over the 5‐year follow‐up. Conversely, multimorbidity (aOR 0.44, 95% CI: 0.44 [0.23−0.84], p = 0.013) and CD4 counts< 500 cells/mm 3 (aOR 0.25, 95% CI: 0.10−0.62, p = 0.003) were associated with a lower likelihood of frailty reversal. Conclusions: Frailty among PWH aged ≥50 years in Thailand was common and highly dynamic, with over half of frail participants improving over 5 years. Multimorbidity, prolonged ART exposure and vitamin D deficiency were key predictors of frailty progression, whereas CD4< 500 cells/mm 3 and multimorbidity reduced the likelihood of frailty reversal. These findings highlight frailty as modifiable and support integrating routine frailty screening and geriatric‐informed care into long‐term HIV services. Clinical Trial Registration: NCT00411983


22 April 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JBJason V Baker
Jason V Baker
LSLianne K Siegel
Lianne K Siegel
MLMarcelo H Losso
Marcelo H Losso
SVShikha Vasudeva
Shikha Vasudeva
JNJacqueline A Nordwall
Jacqueline A Nordwall
CRCavan Reilly
Cavan Reilly
Background: Antivirals remain an important treatment strategy for persons who experience severe and life-threatening COVID-19. Ensitrelvir is an oral 3CL protease inhibitor with potent antiviral activity. Methods: We conducted an international randomized, placebo-controlled trial of ensitrelvir with standard of care (SOC) among adults hospitalized for COVID-19. The primary outcome was clinical recovery assessed by the days to recovery scale through day 60 (DRS-60), analyzed using a Van Elteren test. Results: From 2023 to 2025, 589 participants received blinded study treatment (293 ensitrelvir and 296 placebo). Median age was 69 years, 49% were female, 68% were White, and SOC commonly included corticosteroids (61% and 54%) and remdesivir (62% and 60%) in ensitrelvir and placebo groups, respectively. Median DRS-60 category was 6 (IQR: 3-15) in the ensitrelvir and 5.5 (IQR: 3-12) in the placebo group (P = .19), and the OR was 0.82 (95% CI: 0.62-1.09) for a better DRS-60 category with ensitrelvir. Ensitrelvir participants had lower detectable viral antigen in plasma at Day 5 (13.4% vs 25.1%; P < .001). There was no difference in secondary clinical outcomes or prespecified safety outcomes, though the mortality rate was 6.1% vs 4.4% and the frequency of hemorrhagic events was 3.4% vs 0.3% among ensitrelvir and placebo groups, respectively. Conclusions: Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared with earlier periods in the COVID-19 pandemic and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.